161511-90-6

Basic information

• Product Name: (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL
• Synonyms: 1-Azetidinecarboxylicacid, 2-(hydroxymethyl)-, 1,1-dimethylethyl ester, (2R)-;(R)-2-HYDROXYMETHYL-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;(R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL;(R)-1-BOC-2-AZETIDINEMETHANOL;(R)-1-Boc-2-azetidinemeth...;(R)-tert-butyl 2-(hydroxyMethyl)azetidine-1-carboxylate;(R)-1-(tert-Butoxycarbonyl)-2-azetidineMethanol;tert-butyl (2R)-2-(hydroxymethyl)azetidine-1-carboxylate
• CAS NO: 161511-90-6
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187.24
• Product Categories: Azetidines;Chiral Building Blocks;Glycidyl Compounds, etc. (Chiral);Simple 4-Membered Ring Compounds;Synthetic Organic Chemistry
• Mol File: 161511-90-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 270.349 °C at 760 mmHg
• Flash Point: 117.303 °C
• Appearance: /
• Density: 1.116 g/cm³
• Refractive Index: 1.4580-1.4620
• Storage Temp.: 2-8°C
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL(161511-90-6)
• EPA Substance Registry System: (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL(161511-90-6)

Safety Data

• Hazardous Substances Data: 161511-90-6(Hazardous Substances Data)

Usage

Description

(R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL, also known as (2R)-1-Boc-2-(hydroxymethyl)azetidine, is a chemical compound with a unique structure that has found applications in the pharmaceutical industry. It is characterized by its tert-butoxycarbonyl (Boc) group and azetidine ring, which contribute to its potential uses in drug development and synthesis.

Uses

Used in Pharmaceutical Industry:
(R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL is used as a key intermediate in the synthesis of various pharmaceutical compounds, particularly for the development of oral analgesics. Its unique structure allows for efficient asymmetric synthesis, which is crucial in creating effective and selective pain-relieving medications.
Used in Pain Management Research:
In the field of pain management, (R)-1-(TERT-BUTOXYCARBONYL)-2-AZETIDINEMETHANOL has been utilized to study the structure-activity relationship of (azetidinylmethoxy)chloropyridine derivatives. This research helps in understanding the molecular interactions and mechanisms behind the analgesic effects of these compounds, ultimately leading to the development of more potent and safer pain-relieving drugs.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 95729-87-6 benzyl (2R)-4-oxoazetidine-2-carboxylate 
• 209329-11-3 (2R)-2-azetidinylmethanol 
• 228857-58-7 (R)-N-(tert-butoxycarbonyl)azetidine-2-carboxylic acid 

Downstream Products

• 935668-80-7 (R)-azetidin-2-ylmethanol hydrochloride 
• 887626-82-6 (R)-tert-butyl 2-(aminomethyl)azetidine-1-carboxylate 
• 1434047-88-7 (R)-tert-butyl 2-((5-(phenylethynyl)pyridin-3-yloxy)methyl)azetidine-1-carboxylate 
• 228867-09-2 (R)-tert-butyl 2-((5-bromopyridin-3-yloxy)methyl)azetidine-1-carboxylate 
• 1217413-72-3 tert-butyl (2R)-2-{[2-({(3E)-5-tert-butyl-1-methyl-2-[(2R)-tetrahydrofuran-2-ylmethyl]-1,2-dihydro-3H-pyrazol-3-ylidene}carbamoyl)-4-(trifluoromethyl)phenoxy]methyl}azetidine-1-carboxylate 
• 1215230-32-2 tert-butyl (2R)-2-{[2-{[(2Z)-5-tert-butyl-3-[(2R)-tetrahydrofuran-2-ylmethyl]-1,3-thiazol-2(3H)-ylidene]carbamoyl}-4-(trifluoromethyl)phenoxy]methyl}azetidine-1-carboxylate 
• 209328-49-4 (R)-2-(toluene-4-sulfonyloxymethyl)azetidinecarboxylic acid tert-butyl ester 
• 1005756-63-7 (R)-tert-butyl 2-(azidomethyl)azetidine-1-carboxylate 

Relevant articles and documents

Two Scalable Syntheses of (S)-2-Methylazetidine

Two orthogonal routes for preparing (S)-2-methylazetidine as a bench stable, crystalline (R)-(-)-CSA salt are presented. One route features the in situ generation and cyclization of a 1,3-bis-triflate to form the azetidine ring, while the second route inv

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).